The use of the approved medication Trikafta (elexacaftor/tezacaftor/ivacaftor) was shown to significantly increase weight in people with cystic fibrosis-related…
Articles by Patricia Inácio, PhD
The European Commission has granted orphan drug designation to ARCT-032, an inhaled experimental treatment for cystic fibrosis (CF) developed by…
People with cystic fibrosis (CF) can have abnormal levels or metabolism of three “essential nutrients” — vitamin D, calcium,…
Up to almost 30% of teenagers and adults with cystic fibrosis (CF) in the U.S. have…
An eight-week remote exercise program of moderate to high intensity increased leg muscle strength and reduced body fat in adults…
The Cystic Fibrosis Foundation has announced new funding of up to $15 million to Prime Medicine to further develop…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease status to 4D-710, an inhaled gene therapy for…
Elevated levels of fecal calprotectin, measured over 1.5 years, significantly associated with poorer lung function in children with cystic…
In people with cystic fibrosis (CF), six months of treatment with Kaftrio — sold as Trikafta in the…
Restless legs syndrome (RLS), a disorder characterized by an irresistible urge to move legs or other body parts, especially…